Obesity and colon cancer

Share This Post

According to a recent study  published in JAMA Oncology, obesity is  associated with an increased risk of early-onset colorectal cancer (CRC) in women.

A medical doctor from Boston Massachusetts General Hospital conducted a study to determine the occurrence of colorectal cancer in 85,256 women without cancer and inflammatory bowel disease based on data from 25-42 -year-old women .

The researchers discovered 114 cases of early-onset CRC (median age at diagnosis, 45 years) during the study period . For overweight women (body mass index [BMI] , 25-29.9 kg / m² ) and obese women (BMI, ≥30 kg / m²) with standard weight ( BMI is 18.5-22.9 kg / m² ) compared with women, CRC increased risk . This finding can be attributed to BMI at 18 years of age and weight gain after 18 years of age. For every 5 units of BMI increase , the RR (relative risk) of colorectal cancer increases by 1.2 . Comparative 18 years old BMI was 18.5-20.9 kg m² / female, BMI is 21 – 22.9 kg / m² women, early onset CRC of RRIs 1.32 , BMI is ≥23kg female RR was 1.63 . Similarly, compared with women who gained less than 5 kg or lost weight, women had an increase of 20-39.9 kg in early-onset CRC with an RR of 1.65 , women with an increase of ≥40 kg and an RR of 2.15.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy